7 резултати
EXAMPLE I
Preparation of 2,3-Dihydro-5,6-diphenyl-1,4-oxathiin from 2-Phenylacetophenone and 2-Mercaptoethanol. (Method A)
Powdered 2-phenylacetophenone (1021 g., mp. 55.degree.-57.degree.) was charged into a three-necked flask equipped with a strong mechanical stirrer, a reflux condenser and a
FIELD OF THE INVENTION
The present invention relates to 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide, which is a compound of formula
##STR00002## and to pharmaceutically acceptable acid addition salts thereof. This compound is generically
BACKGROUND OF THE INVENTION
The present invention generally relates to pyridone substituted benzothiazole compounds that are adenosine receptor ligands. Specifically, the compounds of the present invention have a good affinity to the A.sub.2A -receptor and a high selectivity to the A.sub.1 - and
BACKGROUND OF THE INVENTION
Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive
BACKGROUND OF THE INVENTION
Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive
FIELD OF THE INVENTION
The present invention relates to the treatment of inflammatory diseases, including a variety of pulmonary diseases, through the use or administration of nicotinic receptor agonists.
BACKGROUND OF THE INVENTION
Although we breathe more than one cubic meter of air every hour,
FIELD OF INVENTION
The invention relates to a compound of formula ##STR1##
wherein R.sup.1 is selected from the group consisting of hydrogen and fluoro. Compounds of formula 1, and pharmaceutically acceptable acid addition salts thereof, have been shown to mediate the Neurokinin 1 (NK-1, substance